Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JW Therapeutics (Shanghai) Co. Ltd.

www.jwtherapeutics.com

Latest From JW Therapeutics (Shanghai) Co. Ltd.

Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A

China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.

Deals Financing

Finance Watch: Despite Bad News, IPOs And Public Offerings Keep Flowing

Solid Biosciences was able to launch an IPO earlier this year despite a last minute disclosure about a partial clinical hold, which is now a full clinical hold that's cost investors money. Even so, Arcus Biosciences was able to launch its IPO. Ideaya, JW lead recent VC financings.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • JW Therapeutics (Shanghai) Co. Ltd.
  • Senior Management
  • James Li, MD, CEO
  • Contact Info
  • JW Therapeutics (Shanghai) Co. Ltd.
    Phone: 21 50464201
    2F-B, No. 227, Meisheng Rd.
    Shanghai, 200131
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register